Fibroblast growth factor 23: Friend or foe in uremia?

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Uremia is a complex metabolic state marked by derangement of many signaling molecules and metabolic intermediates; of these, the massively increased levels of FGF23 are among the most striking. It has remained unclear whether FGF23 is directly implicated in the pathogenesis of chronic kidney disease (CKD) and its complications, a consequence of other dysregulated pathways, or perhaps an adaptive - and thus desirable - response. In this issue of the JCI, Shalhoub et al. describe the chronic effects of antibody-mediated FGF23 neutralization in a CKD mouse model, shedding new light on this complicated story and moving us one step closer to understanding the role of FGF23 in CKD.

Original languageEnglish (US)
Pages (from-to)2354-2356
Number of pages3
JournalJournal of Clinical Investigation
Volume122
Issue number7
DOIs
StatePublished - Jul 2 2012

Fingerprint

Uremia
Chronic Renal Insufficiency
Antibodies
fibroblast growth factor 23

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fibroblast growth factor 23 : Friend or foe in uremia? / Moe, Orson W.

In: Journal of Clinical Investigation, Vol. 122, No. 7, 02.07.2012, p. 2354-2356.

Research output: Contribution to journalArticle

@article{a9e796e4ecea4a8795f32206155be85f,
title = "Fibroblast growth factor 23: Friend or foe in uremia?",
abstract = "Uremia is a complex metabolic state marked by derangement of many signaling molecules and metabolic intermediates; of these, the massively increased levels of FGF23 are among the most striking. It has remained unclear whether FGF23 is directly implicated in the pathogenesis of chronic kidney disease (CKD) and its complications, a consequence of other dysregulated pathways, or perhaps an adaptive - and thus desirable - response. In this issue of the JCI, Shalhoub et al. describe the chronic effects of antibody-mediated FGF23 neutralization in a CKD mouse model, shedding new light on this complicated story and moving us one step closer to understanding the role of FGF23 in CKD.",
author = "Moe, {Orson W.}",
year = "2012",
month = "7",
day = "2",
doi = "10.1172/JCI64184",
language = "English (US)",
volume = "122",
pages = "2354--2356",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "7",

}

TY - JOUR

T1 - Fibroblast growth factor 23

T2 - Friend or foe in uremia?

AU - Moe, Orson W.

PY - 2012/7/2

Y1 - 2012/7/2

N2 - Uremia is a complex metabolic state marked by derangement of many signaling molecules and metabolic intermediates; of these, the massively increased levels of FGF23 are among the most striking. It has remained unclear whether FGF23 is directly implicated in the pathogenesis of chronic kidney disease (CKD) and its complications, a consequence of other dysregulated pathways, or perhaps an adaptive - and thus desirable - response. In this issue of the JCI, Shalhoub et al. describe the chronic effects of antibody-mediated FGF23 neutralization in a CKD mouse model, shedding new light on this complicated story and moving us one step closer to understanding the role of FGF23 in CKD.

AB - Uremia is a complex metabolic state marked by derangement of many signaling molecules and metabolic intermediates; of these, the massively increased levels of FGF23 are among the most striking. It has remained unclear whether FGF23 is directly implicated in the pathogenesis of chronic kidney disease (CKD) and its complications, a consequence of other dysregulated pathways, or perhaps an adaptive - and thus desirable - response. In this issue of the JCI, Shalhoub et al. describe the chronic effects of antibody-mediated FGF23 neutralization in a CKD mouse model, shedding new light on this complicated story and moving us one step closer to understanding the role of FGF23 in CKD.

UR - http://www.scopus.com/inward/record.url?scp=84863550126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863550126&partnerID=8YFLogxK

U2 - 10.1172/JCI64184

DO - 10.1172/JCI64184

M3 - Article

C2 - 22728930

AN - SCOPUS:84863550126

VL - 122

SP - 2354

EP - 2356

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 7

ER -